GLORIA

GEOMAR Library Ocean Research Information Access

Your email was sent successfully. Check your inbox.

An error occurred while sending the email. Please try again.

Proceed reservation?

Export
Filter
Material
Language
Subjects(RVK)
  • 1
    In: Platelets, Informa UK Limited, Vol. 20, No. 4 ( 2009-01), p. 282-287
    Type of Medium: Online Resource
    ISSN: 0953-7104 , 1369-1635
    Language: English
    Publisher: Informa UK Limited
    Publication Date: 2009
    detail.hit.zdb_id: 2008783-4
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
  • 2
    In: Clinical Chemistry and Laboratory Medicine (CCLM), Walter de Gruyter GmbH, Vol. 50, No. 2 ( 2012-01-1)
    Abstract: In acute myeloid leukemia (AML), the internal tandem duplication (ITD) in the juxtamembrane domain of the A complex evaluation of the analytical properties of the three most frequently used detection methods – PCR followed by agarose (AGE), polyacrylamide (PAGE) or capillary electrophoresis (CE) – was performed on 95 DNA samples obtained from 73 AML patients. All the three methods verified the presence of a mutant allele in 20 samples from 18 patients. AGE and PAGE could detect the presence of 1%–2% mutant allele, while the detection limit of CE was 0.28%. However, acceptable reproducibility (inter-assay CV 〈 25%) of the mutant allele rate determination was only achievable above 1.5% mutant/total allele rate. The reproducibility of the ITD size determination by CE was much better, but the ITD size calculated by PeakScanner or GeneScan analysis was 7% lower as compared to values obtained by DNA sequencing. The presence of multiple ITD was over-estimated by PAGE and AGE due to the formation of heteroduplexes. This study suggests the use of PCR+CE in the diagnostics and the follow-up of AML patients. The data further supports the importance of proper analytical evaluation of home-made molecular biological diagnostic tests.
    Type of Medium: Online Resource
    ISSN: 1437-4331 , 1434-6621
    Language: Unknown
    Publisher: Walter de Gruyter GmbH
    Publication Date: 2012
    detail.hit.zdb_id: 1492732-9
    SSG: 15,3
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
  • 3
    In: Thrombosis Research, Elsevier BV, Vol. 86, No. 2 ( 1997-4), p. 173-180
    Type of Medium: Online Resource
    ISSN: 0049-3848
    Language: English
    Publisher: Elsevier BV
    Publication Date: 1997
    detail.hit.zdb_id: 1500780-7
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
  • 4
    In: European Journal of Haematology, Wiley, Vol. 105, No. 4 ( 2020-10), p. 408-418
    Abstract: We report an extension study of patients with essential thrombocythaemia (ET) in the Hungarian Myeloproliferative Neoplasm (HUMYPRON) Registry, which demonstrated that over 6 years anagrelide significantly decreased the number of patients experiencing minor arterial and minor venous thrombotic events (TEs) vs hydroxyurea+aspirin. Methods Data on patients with ET were collected through completion of a questionnaire developed according to 2008 WHO diagnostic criteria and with regard to Landolfi, Tefferi and IPSET criteria for thrombotic risk. Data were entered into the registry from 14 haematological centres. TEs, secondary malignancies, disease progression and survival were compared between patients with ET treated with anagrelide (n = 116) and with hydroxyurea+aspirin (n = 121). Results Patients were followed for (median) 10 years. A between‐group difference in the number of patients with TEs was observed (25.9% anagrelide vs 38.0% hydroxyurea+aspirin; P  = .052). Minor arterial events were more frequently reported in the hydroxyurea+aspirin group ( P  〈  .001); there were marginally more reports of major arterial events in the anagrelide group ( P  = .049). TE prior to diagnosis was found to significantly influence TE incidence ( P  〉  .001). Progression‐free survival ( P  = .004) and survival ( P  = .001) were significantly increased for the anagrelide group vs hydroxyurea+aspirin. Conclusions Anagrelide reduced TEs, and increased progression‐free and overall survival vs hydroxyurea+aspirin over (median) 10 years.
    Type of Medium: Online Resource
    ISSN: 0902-4441 , 1600-0609
    URL: Issue
    Language: English
    Publisher: Wiley
    Publication Date: 2020
    detail.hit.zdb_id: 2027114-1
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
  • 5
    In: European Journal of Haematology, Wiley, Vol. 98, No. 2 ( 2017-02), p. 106-111
    Abstract: To evaluate the reduction in thrombotic events ( TE ) in patients with essential thrombocythaemia ( ET ) treated with anagrelide versus hydroxyurea + aspirin ( HU + ASA ). Methods A questionnaire was developed using 2008 WHO diagnostic criteria, and thrombotic risk factors were stratified according to Landolfi criteria. Through questionnaire completion, clinicians at Hungarian haematological centres entered data into the Hungarian MPN Registry on patients with myeloproliferative neoplasms. Based on ET registry data, TE s in anagrelide‐treated patients ( n = 139) were compared with HU + ASA ‐treated patients ( n = 141). Results Patients were followed up for (median) 6 yr. TE s were reported in significantly fewer anagrelide‐treated patients versus HU + ASA (15.1% versus 49.6%; P 〈 0.001). Numbers of major arterial and major venous events were similar between the groups, although there were over fivefold more minor arterial and minor venous events in the HU + ASA group ( P 〈 0.001). While median age at diagnosis was older and length of follow‐up shorter in the HU + ASA group ( P 〈 0.05), this did not influence TE incidence; medication and TE before diagnosis only influenced TE incidence. Conclusions Anagrelide significantly decreased the number of patients experiencing minor arterial and minor venous TE s versus HU + ASA over 6 yr. Risk of TE after diagnosis was significantly increased if the patient had TE before diagnosis.
    Type of Medium: Online Resource
    ISSN: 0902-4441 , 1600-0609
    URL: Issue
    Language: English
    Publisher: Wiley
    Publication Date: 2017
    detail.hit.zdb_id: 2027114-1
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
  • 6
    In: Blood, American Society of Hematology, Vol. 132, No. Supplement 1 ( 2018-11-29), p. 4884-4884
    Abstract: Introduction Von Hippel Lindau disease (VHL) is a complex disorder, in which increased oxygen demand of tissues results in a complex setting of neoplastic disorders: i.e. clear cell renal carcinoma, pheochromocytoma, hemangiomas, Lindau tumor, etc., usually appearing well before the age of forty, and usually without polyglobulia. The background of this disease are a series of mutation in VHL gene.This is positioned on the short arm of chromosome 3 (3p25-26). There are over 1500 germline mutations and somatic mutations found or identified in VHL disease. Some rare cases of mutated VHL gene might induce isolated polycythemia, interestingly these cases the other tumors are missing: so it is recommended to check VHL gene in polycythemia if aetiology otherwise not explained. Much less is known about non classical VHL mutations, but just simple VHL polymorphism issues (usually considered innocent, no clinical significance). Wen-Chu Wang et al. BMC Res Notes, 7:628, 2014, VHL polymorphism: Not at all are innocents, at least two single nucleotide polymorphisms of them are not insignificant on clinical grounds. For example Rs779805 polymorphism associates clear renal cell cancer in Taiwan and Mainland China more frequently, but, much less in caucasian population. Somewhat more prostatic and large bowel cancer have been found in this polymorphism, as well. VHL polymorphism Rs1642742: similar disorder association and geographic distribution. However, no blood count abnormalities mentioned in these Chinese reports. Patients and Methods We referred some patient samples gained from eastern Hungary (roughly 2 Million population) with polycythemia like syndrome without Jak2 V617F or exon 12 mutations, no mpl W515 mutation, with low or normal erythropoietin and O2 saturation values (during the past 4 years). We eagerly screened VHL gene in the patients especially if they were young (under 30) or there was evidence of familiar polyglobulia pattern or more cancer. VHL sequenations were performed: VHL gene coding regions: We performed the PCR amplification of intron (IVS1-195-nt) before 1st exon sequences PCR amplification, followed by direct fluorescent sequenation. This work had been performed by Zsuzsanna Bereczky, University Laboratory Medicine institute, her work is kindly acknowledged and highly appreciated Results 1. We have found, even to our surprise,13 patients or probands with the same VHL homo or heterozygous VHL polymorphism, namely the intron (IVS1-195-nt) before the 1st exon: i.e. rs779805 G 〉 A, similar to what had been described in chinese population without blood count abnormalities (but associations with solid tumours) 2. None of the samples so far sequenced revealed true, classical VHL gene mutation. 3. We have found additional cancers in five families: clear renal cell cancer (1), large bowel cancer (2) , melanoma (1) in the same family. more sporadic large bowel cancers, a single Hodgkin lymphoma, bony tumour, gynecological cancers (might or might not be coincidental). There were some patients (during family exploration) who had hemoglobin level over 190 g/L under the age of twenty. 4. Clinical features: Most patients were unusually young. High hemoglobin/red cell count was isolated in most instances, normal white blood cell or platelet counts. Aquagenic pruritus was usually absent, two cases had very mild, atypical itching. Spleen sizes were normal in all cases. In respect of transformation the two-four years observational period is irrelevantly short. Bone marrow examinations were performed in some cases, with normal description and analysis results. We used cautious phlebotomies, targeting 0,52 hematocrit levels. All of them were advised smoking cessation. We performed ultrasound and simple cancer screening on a yearly basis, which we do recommend further on. 5. by chance we identified one young polycythemia patients with same polymorphism and in addition Jak2 V617F mutated status. Conclusions: we do recommend VHL gene sequenation in young patients with otherwise unxplained polyglobulia, especially if there is any sign of familiarity, or unusual precipitation of cancer in the family. We are extending our family screening more deeply, and try to gain data on this polymorphism in 100 young healthy volunteers, analysing their bloofd counts and complex family history. We plan careful hematologic and oncologic followup of our patients and first degree relatives. Disclosures Miklos: Novo nordisk: Honoraria; AOP Orphan: Honoraria.
    Type of Medium: Online Resource
    ISSN: 0006-4971 , 1528-0020
    RVK:
    RVK:
    Language: English
    Publisher: American Society of Hematology
    Publication Date: 2018
    detail.hit.zdb_id: 1468538-3
    detail.hit.zdb_id: 80069-7
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
  • 7
    In: Blood, American Society of Hematology, Vol. 126, No. 23 ( 2015-12-03), p. 5182-5182
    Abstract: Background: The heterogeneity of MPN care in Hungary prompted us to establish the Hungarian MPN Working Group (HUMYPRON GROUP) in year 2012. Aims: The HUMYPRON GROUP created our MPN Registry in 2013, the aims were: (1) to gain epidemiological, diagnostic, therapeutic data, to follow up complications and disease transformations. (2) to investigate the adherence to the WHO/2008 diagnostic criteria and to the Landolfi therapeutic guidelines, to gain insight into vascular and hematological complications (3) to try to identify crucial issues and possible gaps, and promote internationally accepted, standard care in MPN. Methods: There was close cooperation between hematologists and information technicians (IT) experts to create an easily evaluable questionnaire. Data of classical MPN patients were collected from Hungarian centers. The thrombotic risk and the risk adapted treatment characteristics were stratified according to the Landolfi criteria. The data entry was started in 2014. The centers entered the data of all the essential thrombocythemia (ET), polycythemia vera (PV) and idiopathic myelofibrosis (IMF) patients they had diagnosed and treated. In the present work we have analysed the tromboembolic (TE) events that have been observed between the diagnosis and data entry, with special emphasis on iron deficiency. Results: During the first active year of the Hungarian MPN Registry 15 of our major or smaller hematological centers provided patient data, all together reaching the evaluable PV(426)+ET(350) patient number of 776. Because of the method we used entering the data, (all patients of a center) a long follow up period (68 months) was gained, allowing us registering and analyzing 294 TE events. (Table 1) Table 1. Occurence of TE events between diagnosis and data entry period (68 months, 776 PV+ET patients) Amin: 113 TE events Amaj: 18 TE events Vmin: 103 TE events Vmaj: 60 TE events Among the 776 PV/ET patients, the data of iron metabolism were registered in 570 records. 142 of them were iron deficient (47 ET/95 PV). There were 73 TE events registered in 142 iron deficient MPN patients and 140 in the iron non deficient (428 patients) group. The male/female ratio, the median age, the median follow up, the Landolfi risk result were similar in the two groups. Comparing the TE events of iron deficient patients to non iron deficients, significantly more events could have been observed in the former group. (Table 2) Table 2 . Comparison of the TE events in iron deficient /non deficient groups TE events No of pts Male / Female Median age (years) Follow up (months) Landolfi risk result (median) Arterial minor Arterial major Venous minor Venous major Total TE events % of pts having TE Iron defficient 142 63/79 61,2 60 4,59 31 3 26 13 73 51% Non defficient 428 193/235 60,1 62 4,53 57 6 51 26 140 32% The Chi-square statistic is 6.82. The p value is 0.009014. This result is significant at p 〈 0.05. Phlebotomy in PV patients and aspirin in both (PV and ET) groups seemed to be worsening the high thrombotic risk caused by iron deficiency, observed at the time of diagnosis, but the result was not significant. There were 7 major bleeding episodes in the iron deficient group and 12 in the non deficient. Transformation to myelofibrosis occurred in 9 out of 142 patients with iron deficiency and 12 patients in the 428 non iron deficient patients. The p value is 0.06. This result is significant at p 〈 0.1. Conclusions: 1. We have created a national MPN Registry covering a large part of Hungary. The database is operational, online, user friend, easily adjustable to the new professional needs. It is convenient for complex search, correlation and other multiparametric analysis. The data collected so far are in concert with the international epidemiological data. 2. The earlier publications (PVSG) showed iron deficiency as a protective factor in PV patients. Here we report an opposite result, based on the data of a large number of PV+ ET patients and a very long follow up period. When comparing the frequency of the major thrombotic events both group showed the same very low TE frequency, but iron deficiency was found to be significantly inferior when total thrombotic risk and the frequency of minor thrombotic events was evaluated. 3. There were slightly more major bleeding episodes in the iron deficient group. 4. There were significantly more transformation to myelofibrosis in the iron deficient group. Figure 1. Figure 1. Disclosures Judit: Semmelweis University First Department of Internal Medicine, Division of Haematology: Employment, Other: advisory board BMS, Roche, Novartis, Amgen.
    Type of Medium: Online Resource
    ISSN: 0006-4971 , 1528-0020
    RVK:
    RVK:
    Language: English
    Publisher: American Society of Hematology
    Publication Date: 2015
    detail.hit.zdb_id: 1468538-3
    detail.hit.zdb_id: 80069-7
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
  • 8
    In: Blood, American Society of Hematology, Vol. 126, No. 23 ( 2015-12-03), p. 5185-5185
    Abstract: The HUMYPRON GROUP Background: The heterogeneity of MPN care in Hungary prompted us to establish the Hungarian MPN Working Group (HUMYPRON GROUP) in year 2012. Aims: The HUMYPRON GROUP created our MPN Registry in 2013, the aims were: (1) to gain epidemiological, diagnostic, therapeutic data, to follow up complications and disease transformations. (2) to investigate the adherence to the WHO/2008 diagnostic criteria and to the Landolfi therapeutic guidelines, to gain insight into vascular and haematological complications. (3) to try to identify crucial issues and possible gaps, and promote internationally accepted, standard care in MPN. Methods: The questionnaire had been thoroughly updated regarding the 2008 WHO diagnostic criteria (morphology, mutations, etc.) with focus on complications, risk stratification and treatment. The electronic platform can be continuously updated as needed by our steering committee (new molecular results e.g. calreticulin mutations can be included). All haematologists using the system are entitled to initiate search and association analysis. Our MPN Registry is legally permitted by our authorities (ETT-TUKEB) .The data entry was started in 2014. The centers entered the data of all the essential thrombocythaemia (ET), polycythaemia vera (PV)PV and idiopathic myelofibrosis (IMF) patients they had diagnosed and treated. In the present work we have compared the outcome of ET patients treated with either with anagrelid (ANA) or with Hydroxyurea (HU) + aspirin (ASA) based on registry data. Results: During the first active year of the Hungarian MPN Registry 15 of our major or smaller haematological centers provided patient data, all together reaching the evaluable ET patient number of 350. Because of the method we used entering the data, (all patients of a center) a long follow up period was gained, allowing us analyzing effectiveness of different treatment modalities. We have found the data of 141 ET patients, treated with HU + ASA, and 139 ET patients, treated with anaghrelid +/- ASA. There were 65 thrombotic events among the HU+ASA treated group ,while only 25 among the anagrelid group. The major vascular events were the same, but the minor events were different. There were 2 hemorrhagic complications in HU group and 3 in anagrelid group. The male/female ratio, the median age, the follow up period, the Landolfi risk results, the JAK2V617F positivity ratio were comparable between the two groups. We found a significant difference in the frequency of thrombotic events in favour of the anagrelid treatment arm. (Table 1) Table 1. Comparison of Anagrelid versus Hydroxyurrea + aspirin treated ET patients ET/ANA (n=139) ET/HU+ASA (n=141) Gender Male 47 48 Female 92 93 Age et the time of diagnosis (years) Median 60 63 Minimum 25 27 Maximum 92 89 Follow-up time (months) 83 78 JAK V617F mut + (%) 57.0 59.0 Risk stratification according Landolfi (median) 4.56 4.59 Thrombotic events p: 0,000473 25 63 Arterial minor 6 28 Arterial major 2 2 Venous minor 5 27 Venous major 12 6 Major bleeding events 3 2 Progression 5 4 Myelofibrosis 4 3 MDS/AML 0 1 Solid tumor 1 0 Anagrelid was found to be significantly superior when total thrombotic risk and the frequency of minor thrombotic events was evaluated. The Chi-square statistic is 12.2199. The p value is 0.000473. This result is significant at p 〈 0.05 Summary/Conclusion: 1. We have created a national MPN Registry covering a large part of Hungary. The database is operational, online, user friend, easily adjustable to the new professional needs. It is convenient for complex search, correlation and other multiparametric analysis. The data collected so far are in concert with the international epidemiological data. 2. Our first evaluation of two treatment modalities of ET reached a very interesting result. The earlier publications showed superiority of HU based treatments over anagrelid. Here we report an opposite result, based on the data of a large number of ET patients and a very long follow up period. When comparing the frequency of the major thrombotic events both treatments proved equally effective, but anagrelid was found to be significantly superior when total thrombotic risk and the frequency of minor thrombotic events was evaluated. Disclosures Judit: Semmelweis University First Department of Internal Medicine, Division of Haematology: Employment, Other: advisory board BMS, Roche, Novartis, Amgen.
    Type of Medium: Online Resource
    ISSN: 0006-4971 , 1528-0020
    RVK:
    RVK:
    Language: English
    Publisher: American Society of Hematology
    Publication Date: 2015
    detail.hit.zdb_id: 1468538-3
    detail.hit.zdb_id: 80069-7
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
  • 9
    In: Journal of Blood & Lymph, OMICS Publishing Group, Vol. 08, No. 01 ( 2018)
    Type of Medium: Online Resource
    ISSN: 2165-7831
    Language: Unknown
    Publisher: OMICS Publishing Group
    Publication Date: 2018
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
  • 10
    In: Blood, American Society of Hematology, Vol. 120, No. 21 ( 2012-11-16), p. 4889-4889
    Abstract: Abstract 4889 Background: Considering the especially poor outcome of mantle cell lymphoma with traditional induction chemotherapies, the Hungarian working group initiated a Hungarian Mantle Cell Lymphoma Study (REMENY) using rituximab (MabThera) based immunochemotherapy. The structure of the trial: National, multicenter, open label trial rituximab based immunochemotherapy induction in mantle cell lymphoma. Two therapies were available according to investigators' choice: R-CHOP-21 (8x) or R-HyperC-VAD/R-MA according to the MD Anderson protocol. High dose therapy + autologous stem cell support (ASCT) was allowed, according to the investigators decision. Diagnosis was based upon standard histology. Initial staging included the standard protocols, imaging techniques, bone marrow evaluation and gastrointestinal endoscopy (not compulsory at initial staging). Recruitment period was planned to be 3 years, the follow-up 2 years. Remission was evaluated according to Cheson (IWC) criteria,CR was qualified only after completion of gastroscopy and colonoscopy, which did not reveal any mantle cell related abnormality. In some cases FDG PET-CT was allowed to substitute for endoscopy. Primary endpoints: OS and PFS, safety Results: Recruitment started in June 2007 and completed unexpectedly early (Nov 2008). 48 patients were included, per protocol Patients were 31 (64.58%), follow-up (24 months) was completed for 15 (31.25%) patients. Ann Arbor III-IV B 43 (89.58%) was dominant. Median PFS for all patients was 30.4 months (SD 5.839, 95% CI: 19–41.9). PFS median for those patients who reached a CR has not been reached while it was 23.7 months in PR (p=0.031). Safety: One hundred-thirteen adverse events occurred in 31 (64.58%) patients; 53 serious adverse events in 15 (31.25%) patients: 17 cytopenia, including fever with neutropenia 7, transient bronchospasm during rituximab (MabThera) infusion 1, hyperglycemia 1 which may be treatment related. There were 20 death cases, 13 of them due to progression of disease, two due to septic complication, three heart failures and one second malignancy (breast cancer). Significantly more patients on the R-HyperC-VAD/R-MA arm experienced adverse events (11/12 patients, 91.6%) compared to R-CHOP (20/36, 55.5%, p=0.035). Conclusion: This trial further confirmed the value of adding rituximab to standard induction therapies in mantle cell lymphoma. The results are conforming to data published in literature. Higher percentage of patients completed R-CHOP regimen. R-HyperC-VAD/R-MA was more effective in inducing CR, but could be completed only in one third of patients. However, in those patients who adhered to R-HyperC-VAD/R-MA therapy, it resulted in 80% CR, vs. 42.3% in the R-CHOP group. This difference is not statistically significant (p=0.172) possibly due to low case numbers. Those patients who reached CR had significantly longer PFS. PFS obtained in this trial is comparable to international data, and could be further improved by adding immunotherapy maintenance. Planned total number of patients (48) entered the trial during the first 12 months. This was surprising, as the expected number of mantle cell lymphoma based on the international incidence data is cca. 30–35 yearly. The unexpectedly high patient numbers need further explanation. Disclosures: Off Label Use: Rituximab is not authorized for Mantle Cell Lymphoma in Hungary.
    Type of Medium: Online Resource
    ISSN: 0006-4971 , 1528-0020
    RVK:
    RVK:
    Language: English
    Publisher: American Society of Hematology
    Publication Date: 2012
    detail.hit.zdb_id: 1468538-3
    detail.hit.zdb_id: 80069-7
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
Close ⊗
This website uses cookies and the analysis tool Matomo. More information can be found here...